Avenue Solutions

Avenue Solutions filed a Q2 report for Edwards Lifesciences LLC on July 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Edwards Lifesciences LLC · Patient-focused innovations for structural heart disease and critical care monitoring

As filed: AVENUE SOLUTIONS for EDWARDS LIFESCIENCES LLC.

All filings by Avenue Solutions · Everything Edwards Lifesciences LLC has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to CMSs draft coverage policy for transcatheter aortic valve replacement (TAVR) issued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Bills named in this filing 2

H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.